Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma Academic Article uri icon

Overview

MeSH Major

  • Lymphoma, Mantle-Cell
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Pyrazoles
  • Pyrimidines

abstract

  • Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)

authors

publication date

  • August 13, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4513941

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1306220

PubMed ID

  • 23782157

Additional Document Info

start page

  • 507

end page

  • 16

volume

  • 369

number

  • 6